Myeloma Trial, Recruiting NCT06644625 Sponsor: Wake Forest University Health Sciences Condition: Myeloma
Back to Myeloma

Myeloma Trial, Recruiting

NCT06644625
Recruiting Not Applicable

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

  • People who are 30 years of age or older at the time of signing up
  • People who identify as Black and/or African American, OR people of any race or ethnicity who have a close family member (parent, sibling, or child) who has been diagnosed with a plasma cell disorder, such as MGUS, smoldering multiple myeloma, multiple myeloma, solitary plasmacytoma, plasma cell leukemia, AL amyloidosis, POEMS syndrome, or Waldenström's Macroglobulinemia
  • People who are able and willing to give their informed consent to participate
  • People who live in Charlotte, NC, or the surrounding area (based on self-report)
  • For the longer-term follow-up part of the study: people who test positive for a monoclonal gammopathy (an abnormal protein in the blood) during the screening part of the study, and who agree to continue participating

Who may not be able to join:

  • People who already have a personal history of MGUS, smoldering multiple myeloma, multiple myeloma, AL amyloidosis, plasma cell leukemia, solitary plasmacytoma, Waldenström's Macroglobulinemia, or POEMS syndrome
  • For the longer-term follow-up part of the study: people who previously took part in the CHAAMP Internal Pilot study and completed diagnostic testing at that time without receiving a diagnosis of MGUS, smoldering multiple myeloma, or a related plasma cell disorder

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.
Last synced 23 July 2026
This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: Manisha Bhutani, MD, Atrium Health Wake Forest Baptist Comprehensive Cancer Center

Phone: 704-754-3768

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Trial details

Status
Recruiting
Phase
Not Applicable
Registry
ClinicalTrials.gov
Start date
1 March 2025
Est. completion
1 January 2035

Where this trial is recruiting

🇺🇸 United States

Primary endpoints

Number of Participants who were Enrolled

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 23 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov